This is a summary of the European public assessment report (EPAR) for Lojuxta. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Lojuxta. For practical information about using Lojuxta, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Lojuxta is indicated as an adjunct to a low?fat diet and other lipid?lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH). Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.
Therapeutic Area (MeSH)
ATC Code
C10AX12
ATC Item
lomitapide
Pharmacotherapeutic Group
Lipid modifying agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Lomitapide | N/A | 洛美他派 |
EMA Name
Lojuxta
Medicine Name
Lojuxta
Aliases
N/ANo risk management plan link.
